Gabather
1.685 SEK +11.22%1 investor is following this company
Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GABA
Daily low / high price
1.415 / 1.72
SEK
Market cap
31.82M SEK
Turnover
29.81K SEK
Volume
19K
Financial calendar
Interim report
2024-08-29
Interim report
2024-11-28
Annual report
2025-02-27
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 14.4 % | 14.4 % |
Investment Aktiebolaget Balticum | 2.4 % | 2.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Gabather AB offentliggör årsredovisning för räkenskapsåret 2023
Gabather AB: Gabather publicerar delårsrapport 1 januari - 31 mars 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools